LexDanaLexDanabeta
Inventor

Mark Whittaker

Inventor
Oxford, GB

Overview

74→
Patents
1993–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 74 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
C07DHeterocyclic compounds27%
A61KPreparations for medical, dental or toiletry purposes16%
C07CAcyclic or carbocyclic compounds15%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
C07KPeptides3%
LOC151%
Y02ATechnologies for adaptation to climate change1%
Y02PClimate change mitigation technologies in the production or processing of goods1%
A45CPurses0%
PatentTitleYear
11,091,428Antiviral compounds202110,472,341Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases2019D0798913'Combined mulching tooth and depth limiter'20178,980,927'Compounds having CRTH2 antagonist activity'20158,759,520'Compounds for treating cancer'2014D0699269'Combined mulching tooth and holder'20148,609,696'Serotonin 5-HT2B receptor inhibitors'20138,592,430'Quinazolin-oxime derivatives as Hsp90 inhibitors'20138,563,536'Compounds having CRTH2 antagonist activity'20138,536,158'Compounds having CRTH2 antagonist activity'20138,314,257'Treatment of CRTH2-mediated diseases and conditions'20128,206,045'Hands-free camera holder'20128,198,314'Treatment of CRTH2-mediated diseases and conditions'20128,163,931'Treatment of CRTH2-mediated diseases and conditions'20128,163,936'Treatment of CRTH2-mediated diseases and conditions'20127,919,512'Compounds having CRTH2 antagonist activity'20117,750,027'Compounds having CRTH2 antagonist activity'20107,582,672'Compounds for the treatment of CRTH2-mediated diseases and conditions'20097,323,448'Antibacterial agents'20087,323,563'Hydroxamic acid derivatives as antibacterials'20087,148,198'Antibacterial agents'20066,992,190'Hydroxamic acid derivatives as antibacterials'20066,908,911'Antibacterial agents'20056,787,522'Antibacterial agents'20046,635,621'Cysteine protease inhibitors'20036,569,847'Substituted azetidin-2-ones as cysteine protease inhibitors'20036,545,051'Antibacterial hydroxamic acid derivatives'20036,503,897'Antibacterial agents'20036,476,067'N-formyl hydroxylamine derivatives as antibacterial agents'20026,441,042'Hydroxamic acid derivatives as antibacterials'20026,423,690'Antibacterial agents'20026,358,987'Metalloproteinase inhibitors'20026,329,373'Metalloproteinase inhibitors'20016,306,881'Anti-inflammatory agents'20016,271,262'Metalloproteinase inhibitors'20016,258,851'Metalloproteinase inhibitors'20016,127,427'Metalloproteinase inhibitors'20006,124,332'Metalloproteinase inhibitors'20006,124,329'Metalloproteinase inhibitors'20006,124,333'Metalloproteinase inhibitors'20006,103,739'Metalloproteinase inhibitors'20006,028,110'Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors'20006,022,873'Metalloproteinase inhibitors'20006,022,898'Metalloproteinase inhibitors'20006,017,889'Metalloproteinase inhibitors'20005,962,529'Metalloproteinase inhibitors'19995,908,851'Derivatives of succinamide and their use as metalloproteinase inhibitor'19995,902,791'Metalloproteinase inhibitors'19995,866,717'Metalloproteinase inhibitors'19995,866,588'Imidazopyridine derivatives'19995,861,436'Hydroxamic acid derivatives as metalloproteinase inhibitors'19995,859,253'Metalloproteinase inhibitors'19995,849,951'Synthesis of carboxylic and hydroxamic acid derivatives'19985,840,974'Metalloproteinase inhibitors'19985,840,939'Derivatives of succinamide and their use as metalloproteinase inhibitors'19985,763,621'Metalloproteinase inhibitors'19985,753,671'Imidazopyridine derivatives as dual histamine (H.sub.1) and platelet activating factor (PAF) antagonists'19985,747,514'Metalloproteinase inhibitors'19985,741,794'Heterocyclic sulfonamide derivatives as antagonists of PAF and angiotensin II'19985,673,464'Cargo securement system and tie down strap'19975,637,595'Cyclic ether acetal PAF antagonists'19975,563,151'Amino acid derivatives as paf-receptor antagonists'19965,516,783'4-(1H-2-methylimidazo[4,5-c]pyridinylmethyl)phenylsulphonamide derivatives as antagonist of PAF'19965,451,676'Biphenyl ether heterobicyclic platelet activating factor antagonists'19955,446,032'Imidazo (4,5-C) pyridine derivatives as PAF antagonists'19955,428,168'Lactol PAF antagonists'19955,409,937'Hexahydrofuro(2,3-b)furans as PAF antagonists'19955,314,880'Benzimidazole derivatives'19945,300,524'Spirocyclic PAF antagonists'19945,276,153'Production of certain imidazopyridinyl-methyl-benzene sulfonamides'19945,274,094'Production of heterobicyclic containing benzene sulfonamides'19935,200,412'Heterobicyclic containing benzene sulfonamides which are platelet activating factor antagonists'19935,180,724'Carboxamide amino acid heterobicyclic PAF antagonists'19935,180,723'Certain sulfonamide heterobicyclic platelet activating factor antagonists'1993

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1993–1997Patents assigned to BRITISH BIO TECHNOLOGY (8)· patent assignee history
1993–2008Based in Oxford, GB· patent location history
1993–2019Based in Oxfordshire, GB· patent location history
1995–2008Patents assigned to BRITISH BIOTECH PHARM (43)· patent assignee history
1998–2008Based in Cowley, GB· patent location history
1998Based in Oxford, PA, US· patent location history
2003–2021Based in Abingdon, GB· patent location history
2009–2012Patents assigned to OXAGEN LTD (7)· patent assignee history
2012–2014Patents assigned to WHITTAKER MARK (10)· patent assignee history
2012Patents assigned to ASHTON MARK RICHARD (4)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
BRITISH BIOTECH PHARM431995–2008
WHITTAKER MARKself102012–2014
BRITISH BIO TECHNOLOGY81993–1997
OXAGEN LTD72009–2012
ASHTON MARK RICHARD42012
Locations
LocationPatentsSpan
Oxford, GB321993–2008
Abingdon, GB102003–2021
Cowley, GB91998–2008
Oxford, Pennsylvania, US61998
Oxfordshire, GB51993–2019